- Case report
- Open Access
A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report
© Todoroki et al; licensee BioMed Central Ltd. 2006
- Received: 04 February 2006
- Accepted: 25 August 2006
- Published: 25 August 2006
Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
A 71-year-old female was referred to our hospital because of a large right inguinal tumor with biopsy evidence of carcinoma as well as an elevated serum CA125 (cancer antigen 125). She underwent complete resection of the right inguinal tumor and multiple pelvic tumors, which involved the rectum, ovary and uterus. Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP. On the 28th postoperative day, newly developed asymptomatic small left inguinal node metastases in the setting of a normal CA125 level were removed. Four and a half years after the primary resection, the CA125 level increased again and newly developed asymptomatic metastases were found in the right deep inguinal nodes and extirpated at that time. All surgical resections followed the modified FAM (5FU, Adriamycin; ADM, MMC) regimen, including protracted dairy oral administration of UFT or 5'-FDUR, Cimetidine and PSK (protein-bound polysaccharide K) as an immunomodulator or biological response modifier in conjunction with intermittent one-day continuous infusion (ADM+MMC) or intermittent single bolus injection of ADM+MMC. At present, the patient has been living in good health for almost 7 years with no evidence of relapse.
Aggressive resection surgery followed by effective adjuvant chemotherapy is necessary for surviving long time without relapse of poorly prognostic patients with metastases outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.
- Intermittent Infusion
- Biological Response Modifier
- Psammoma Body
- Complete Tumor Removal
Despite recent advances in diagnostic imaging and molecular pathology, CUP accounts for about 3 % of all malignant neoplasms, which represent a group of heterogeneous tumors sharing unique clinical characteristics of metastatic epithelial cancers with no identifiable origin even on autopsy . The heterogeneity of CUPs in their clinical presentations, histologic types and natural histories has rendered accurate diagnosis and appropriate treatment strategies difficult. Female patients with peritoneal papillary serous carcinomatosis form a subset of patients who respond favorably to cisplatin-based chemotherapy; however, metastases outside of the peritoneal cavity are unusual and carry a dismal prognosis [2, 3]. There is no standard chemotherapeutic regimen for repeated metastases outside of the peritoneal cavity in cases of peritoneal papillary serous adenocarcinomatosis .
Herein, we present a female patient with repeated bilateral inguinal lymph node metastases from peritoneal papillary serous adenocarcinomatosis of CUP, who is alive and well almost 7 years after the initiation of therapy involving multiple resection surgeries and unique adjuvant chemoimmunotherapy.
Present history and preoperative examination
CT on the 23rd postoperative day demonstrated new small asymptomatic inguinal tumors adjacent to the left external iliac artery. The diameter of those tumors was 15 mm and 12 mm, respectively. Those tumors were extirpated completely on July 29, 1999.
Operative procedures and findings
The right inguinal tumor, approximately 4.5 × 5 × 4 cm in diameter, was relatively well circumscribed by the right inguinal ligament, and right external iliac artery and vein, which are supplying and draining tumor blood flow. After extirpation of the inguinal tumors, the intra-pelvic tumors were removed completely by total hysterectomy with salpingo-oophorectomy and a partial resection of the rectum at the rectosigmoid junction (Fig. 1C&1D). There was no direct invasion of the tumor into the urinary bladder and there was no evidence of remaining tumor in the abdominal cavity.
Pathologic findings and diagnosis
Postoperative course and adjuvant therapy
Her postoperative course was uneventful, except for the early detection of the left inguinal node metastasis by CT on the 23rd postoperative day. This tumor was extirpated promptly and postoperative imaging procedures confirmed that no tumor remained anywhere in the body. Pathologic examinations revealed lymph node metastasis from a papillary serous adenocarcinoma (Fig. 2D). Preoperatively, daily oral administration of UFT (450 mg/day) Cimetidine (H2 receptor antagonist; 600 mg/day) and PSK (3 g/day) was started. We used Cimetidine not only as an anti-ulcer drug, but also as an immunomodulator or biological response modifier with the hope of eradicating possible microscopic residual cancer cells [6–8]. PSK was used as an immunomodulator against possible remaining adenocarcinoma cells somewhere in the body of this patient [9, 10]. In order to increase the anti-tumor effect as well as decrease the toxicity, we tried intravenous single-day continuous infusion of low dose combination chemotherapy through a port implanted on the right upper chest wall with an access catheter (Groshong®) to the superior vena cava by way of the right subclavian vein. A portable elastomeric infusion system filled with 50 ml saline dissolution of Mitomycin C (MMC; 6 mg) and Adriamycin (ADM; l0mg) was applied every other week at an outpatient clinic. Three months after we changed from UFT to 5'-FDUR (600 mg/day) because MMC may be more effective with 5'-FDUR (due to stronger inductive activity of thymidine phosphorylase (dThdPase) in tumor tissues [11, 12].
Despite modern imaging technology, including Positron Emission Tomography (PET) scanning, the primary site remains unknown in patients with metastatic CUP, even on autopsy. Metastatic CUP represents a heterogeneous group in terms of clinical presentation, histology and presumably biology. Lymph node involvement, the number of metastatic organ sites, hepatic involvement, and tumor histology have been reported as significant independent prognostic factors . Although the histologic features of our case presented a papillary configuration and psammoma bodies in all of the surgical specimens, no primary site was found in the body or in the ovaries. Taking into account the fact that the epithelial layer of the ovary and the peritoneum share a common origin from the coelomic epithelium embryonically and that repeated elevations of the serum CA19-9 level occurred whenever metastasis had occurred in our case, it is plausible that papillary serous carcinoma of the peritoneum is an analog with ovarian carcinoma or an extraovarian primary peritoneal carcinoma [3, 14]. Clinical experiences in treating patients with inguinal nodes metastases of female peritoneal papillary serous carcinomas have been reported infrequently and there is a lack of a standard chemotherapeutic regimen for this unusual and poor prognostic disease [2, 15]. Cisplatin-based chemotherapy might be a choice in our case, given that favorable response rates [3, 14, 15] have been reported in female peritoneal papillary serous carcinoma cases if metastases outside the peritoneal cavity have not been present. However, we chose modified FAM, because a regimen including 5-FU, ADM and MMC have shown some valuable activity in many adenocarcinomas of the gastrointestinal tract, pancreas, lung and breast, etc. Instead of 5-FU we used UFT and 5'-DFUR, which are synthesized fluoropyrimidine prodrugs of 5-FU for oral administration and have been designed to improve the delivery of 5-FU. Both are intended to increase the anti-cancer efficacy and reduce the toxicity by slow conversion of the drug to fluorouracil through the cytochrome P-450 metabolic pathway  in the former and by dominant delivery of fluorouracil in cancer tissues in the latter . We tried reciprocal enhancement of anti-tumor effects of 5'-DFUR and MMC with anticipation of less toxicity. MMC was used not only tumor cell killing, but also as an up-regulator of dThdPase, which is an essential enzyme to convert 5'-DFUR to 5-FU located more amount than in the non-cancerous tissue . Cimetidine and PSK may have favorable effects as an immunomodulator or biological response modifiers to kill some microscopic residual cancer cells and to prevent possible formation of new metastases by inhibiting cancer cell adhesion to endothelial cells [6–10].
Female patients with metastases to the inguinal nodes from peritoneal papillary serous carcinomas of CUP are rare and have poor prognoses. There is no standard effective chemotherapeutic regimen for these patients. However, complete tumor removal followed by appropriate chemotherapy can lead to long-term survival even if the patient had nodal metastases beyond the abdominal cavity. Our modified FAM using protracted intermittent infusion of low dose MMC/ADM combined with oral UFT/5'-FDUR with PSK/Cimetidine may prove to be an efficient chemotherapeutic regimen with low toxicity, and which is amenable to good compliance.
- Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003, 39: 1990-2005. 10.1016/S0959-8049(03)00547-1.View ArticlePubMedGoogle Scholar
- Hess RK, Abbruzzese CM, Lenzi R, Raber NM, Abbruzzese LJ: Classification and Regression Tree Analysis of 1000 Consecutive Patients with Unknown Primary Carcinoma. Clin Cancer Res. 1999, 5: 3403-3410.PubMedGoogle Scholar
- Greco F, Hainsworth J: Cancer of unknown primary site: In Cancer; principles and practice of oncology. Edited by: DeVita VTJr, Hellman S, Rosenberg S. 2001, Philadelphia: Lippincott Williams and Wilkins, 2: 2537-2560. 6Google Scholar
- Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforet C, Bedossa P, Bertrand G, Coindre J, M.Fizazi K: Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer. 2003, 89 (Suppl 1): S59-66. 10.1038/sj.bjc.6601085.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J, Russell P, Buckley CH, Pisani P, Schwartz P, Goldgar DE, Silva E, Caduff R, Kubik-Huch RA: Surface epithelial-stromal tumours. In World Health Organization classification of tumours: pathology & genetics: tumours of the breast and female genital organs. Edited by: Tavassoli FA, Devilee P. 2003, Lyon: IARC Press, 117-145.Google Scholar
- Kumar A: Cimetidine: an immunomodulator. Dicp. 1990, 24: 289-295.PubMedGoogle Scholar
- Matsumoto S: Cimetidine and survival with colorectal cancer. Lancet. 1995, 34: 6115-Google Scholar
- Adams WJ, Morris DL: Pilot study–cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer. 1997, 80: 15-21. 10.1002/(SICI)1097-0142(19970701)80:1<15::AID-CNCR3>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K, Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S, Ogata T, Ohto H: Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res. 2005, 25: 443-9.PubMedGoogle Scholar
- Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwasaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomized controlled study. Br J Cancer. 2004, 90: 1003-1010. 10.1038/sj.bjc.6601619.PubMed CentralView ArticlePubMedGoogle Scholar
- Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer . 1998, 34: 1274-81. 10.1016/S0959-8049(98)00058-6.View ArticlePubMedGoogle Scholar
- Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998, 4: 1013-9.PubMedGoogle Scholar
- Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH: Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer. 1990, 66: 1091-1094. 10.1002/1097-0142(19900915)66:6<1091::AID-CNCR2820660602>3.0.CO;2-F.View ArticlePubMedGoogle Scholar
- Sumi H, Itoh K, Onozawa Y, Shigeoka Y, Kodama K, Ishizawa K, Fujii H, Minami H, Igarashi T, Sasaki Y: Treatable Subsets in Cancer of Unknown Primary Origin. Jap J Cancer Res. 2001, 92: 704-709.View ArticleGoogle Scholar
- Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforet C, Bedossa P, Bertrand G, Coindre JM, Fizazi K: Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site. Bull Cancer. 2002, 89: 869-75.PubMedGoogle Scholar
- Diasio RB: Current status of oral chemotherapy for colorectal cancer. Oncology (Huntingt). 2001, 15 (3 Suppl 5): 16-20.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.